Fosun Pharma (02696): Globalization of drugs and deep pipeline development: covering markets in 50 countries, targeting the next "tough nut" indication.

Zhitaong Finance APP learned that on June 9, 2026, the New Drug Application (NDA) for the listing registration of Fuhong Hanlin's self-developed anti-PD-1 monoclonal antibody Hantenshuang (Sululit monoclonal antibody, European brand name: Hetronifly) for the indication was officially approved by the National Medical Products Administration (NMPA) through the priority review process, to be used in combination with oxaliplatin and tegafur for neoadjuvant and adjuvant monotherapy for resectable gastric cancer with tumor PD-L1 expression CPS5.